AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21954640 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy
Number of subjects: 0
Study 19269938 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized protocol training for palpatory assessment of the frontomalar suture
Number of subjects: 36
Study 19269938 — intervention group
Group type: COMPARATOR
Intervention: Control group (no instruction)
Number of subjects: 36
Study 16633141 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole pretreatment (200 mg/d for 10 days)
Number of subjects: 19
Study 16633141 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole pretreatment with CYP2D6*10/*10 genotype
Number of subjects: 19
Study 16633141 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6*10 genotype with itraconazole pretreatment
Number of subjects: 19
Study 16633141 — intervention group
Group type: EXPERIMENTAL
Intervention: CYP2D6*10/*10 genotype with itraconazole pretreatment
Number of subjects: 19
Study 16633141 — intervention group
Group type: COMPARATOR
Intervention: Placebo pretreatment
Number of subjects: 19
Study 14983418 — intervention group
Group type: COMPARATOR
Intervention: No treatment control group
Number of subjects: 63
Study 14983418 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstracts from 1998 and 1999
Number of subjects: 63
Study 14983418 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstracts from 1987
Number of subjects: 63
Study 11514765 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamma nail intramedullary fixation device
Number of subjects: 400
Study 11514765 — intervention group
Group type: COMPARATOR
Intervention: Richard's sliding hip screw and plate
Number of subjects: 400
Study 9667721 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective proximal gastric vagotomy (PGV)
Number of subjects: 3
Study 9667721 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment with H2-receptor antagonists
Number of subjects: 3
Study 9667721 — intervention group
Group type: COMPARATOR
Intervention: Community controls
Number of subjects: 3
Study 7851061 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 kg weight in one hand
Number of subjects: 12
Study 7851061 — intervention group
Group type: COMPARATOR
Intervention: no weight
Number of subjects: 12
Study 2901569 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrical nerve stimulation (ENS)
Number of subjects: 24
Study 2901569 — intervention group
Group type: COMPARATOR
Intervention: Placebo-ENS
Number of subjects: 24
Study 29231499 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group (acupuncture plus ginger moxibustion at Heding EX-LE 2)
Number of subjects: 90
Study 29231499 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture group (simple acupuncture at Heding EX-LE 2)
Number of subjects: 90
Study 29231499 — intervention group
Group type: COMPARATOR
Intervention: Ginger moxibustion group (simple ginger moxibustion at Heding EX-LE 2)
Number of subjects: 90
Study 29231499 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination group
Number of subjects: 90
Study 29231499 — intervention group
Group type: COMPARATOR
Intervention: Acupuncture group
Number of subjects: 90
Study 29231499 — intervention group
Group type: COMPARATOR
Intervention: Ginger moxibustion group
Number of subjects: 90
Study 25488262 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus reuteri DSM 17938 (108 cfu) with 400 UI of vitamin D3
Number of subjects: 105
Study 25488262 — intervention group
Group type: COMPARATOR
Intervention: 400 UI of vitamin D3
Number of subjects: 105
Study 23123925 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol (BUD/FM)
Number of subjects: 0
Study 23123925 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (BUD)
Number of subjects: 0
Study 20738748 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% Lawsone Methyl Ether (LME)
Number of subjects: 54
Study 20738748 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.025% Lawsone Methyl Ether (LME)
Number of subjects: 54
Study 20738748 — intervention group
Group type: EXPERIMENTAL
Intervention: Lawsone Methyl Ether (LME)
Number of subjects: 54
Study 20738748 — intervention group
Group type: COMPARATOR
Intervention: 0.12% Chlorhexidine (CHX)
Number of subjects: 54
Study 19103435 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil (200 mg/day)
Number of subjects: 50
Study 19103435 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 16826106 — intervention group
Group type: EXPERIMENTAL
Intervention: Periapatite-coated Duracon implants
Number of subjects: 26
Study 16826106 — intervention group
Group type: COMPARATOR
Intervention: Uncoated Duracon implants
Number of subjects: 26
Study 15247013 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E, 300 mg/day
Number of subjects: 60
Study 15247013 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivitamin, two tablets t.i.d.
Number of subjects: 60
Study 15247013 — intervention group
Group type: EXPERIMENTAL
Intervention: Immun‐Age 6 g/day nocte
Number of subjects: 60
Study 15247013 — intervention group
Group type: COMPARATOR
Intervention: Control group (10 dyspeptic patients)
Number of subjects: 60
Study 11207103 — intervention group
Group type: EXPERIMENTAL
Intervention: Waterbirth pool
Number of subjects: 220
Study 11207103 — intervention group
Group type: EXPERIMENTAL
Intervention: Augmentation of labour
Number of subjects: 220
Study 11207103 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 220
Study 9091151 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc oxide impregnated bandage
Number of subjects: 113
Study 9091151 — intervention group
Group type: COMPARATOR
Intervention: Zinc oxide impregnated stockingette
Number of subjects: 113
Study 9091151 — intervention group
Group type: COMPARATOR
Intervention: Alginate dressing
Number of subjects: 113
Study 8452189 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose fleroxacin (400 mg)
Number of subjects: 961
Study 8452189 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day fleroxacin (200 mg once a day)
Number of subjects: 961
Study 8452189 — intervention group
Group type: COMPARATOR
Intervention: 7-day ciprofloxacin (250 mg twice a day)
Number of subjects: 961
Study 3779034 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifurzide (600 mg single oral dose)
Number of subjects: 0
Study 3779034 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifuroxazide (600 mg single oral dose)
Number of subjects: 0
Study 3779034 — intervention group
Group type: EXPERIMENTAL
Intervention: 14C-nifurzide (10 mg kg-1 in rats)
Number of subjects: 0
Study 3779034 — intervention group
Group type: EXPERIMENTAL
Intervention: 14C-nifuroxazide (10 mg kg-1 in rats)
Number of subjects: 0
Study 3779034 — intervention group
Group type: EXPERIMENTAL
Intervention: 14C-nifuroxazide (in rats)
Number of subjects: 0
Study 3779034 — intervention group
Group type: EXPERIMENTAL
Intervention: 14C-nifurzide (in rats)
Number of subjects: 0
Study 3779034 — intervention group
Group type: EXPERIMENTAL
Intervention: 14C-nifurzide and 14C-nifuroxazide (in rats)
Number of subjects: 0
Study 31740197 — intervention group
Group type: EXPERIMENTAL
Intervention: EPA (1 g per day for 6 days)
Number of subjects: 12
Study 31740197 — intervention group
Group type: EXPERIMENTAL
Intervention: DPA (1 g per day for 6 days)
Number of subjects: 12
Study 31740197 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA (1 g per day for 6 days)
Number of subjects: 12
Study 27635620 — intervention group
Group type: EXPERIMENTAL
Intervention: Preradiation chemotherapy with cisplatin, etoposide, cyclophosphamide, and vincristine followed by craniospinal radiation (CSI)
Number of subjects: 11
Study 26463725 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group (Lactobacillus acidophilus DDS-1 and Bifidobacterium lactis UABLA-12 with 50 mg of fructooligosaccharide)
Number of subjects: 225
Study 26463725 — intervention group
Group type: COMPARATOR
Intervention: Control group (rice maltodextrin)
Number of subjects: 225
Study 26463725 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic group
Number of subjects: 225
Study 25695111 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage N3 (% TST)
Number of subjects: 118
Study 25695111 — intervention group
Group type: EXPERIMENTAL
Intervention: Stage N1 (% TST)
Number of subjects: 118
Study 25695111 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher sleep efficiency
Number of subjects: 118
Study 25695111 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer TST
Number of subjects: 118
Study 23918376 — intervention group
Group type: EXPERIMENTAL
Intervention: Meditation training (5 hours total over 2 weeks)
Number of subjects: 0
Study 23918376 — intervention group
Group type: COMPARATOR
Intervention: Relaxation training control
Number of subjects: 0
Study 20634131 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS at 5 Hz
Number of subjects: 9
Study 20634131 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS at 25 Hz
Number of subjects: 9
Study 20634131 — intervention group
Group type: EXPERIMENTAL
Intervention: TENS at 50 Hz
Number of subjects: 9
Study 18333763 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual breast pump
Number of subjects: 280
Study 18333763 — intervention group
Group type: COMPARATOR
Intervention: Electric breast pump
Number of subjects: 280
Study 16830932 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG-derived method for estimating respiratory frequency
Number of subjects: 34
Study 14667998 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg onapristone
Number of subjects: 17
Study 14667998 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg onapristone
Number of subjects: 17
Study 14667998 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 14667998 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of oestradiol
Number of subjects: 17
Study 10923059 — intervention group
Group type: EXPERIMENTAL
Intervention: Critical tests administered at the beginning and end of the session
Number of subjects: 351
Study 10923059 — intervention group
Group type: COMPARATOR
Intervention: Critical tests administered only once, at the end of the session
Number of subjects: 351
Study 9678101 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral contraceptives (OCs) for 36 months
Number of subjects: 17
Study 9678101 — intervention group
Group type: COMPARATOR
Intervention: Control group (no OCs)
Number of subjects: 17
Study 8099592 — intervention group
Group type: EXPERIMENTAL
Intervention: Azelastine
Number of subjects: 10
Study 8099592 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 3558328 — intervention group
Group type: EXPERIMENTAL
Intervention: lorazepam 1 mg
Number of subjects: 30
Study 3558328 — intervention group
Group type: EXPERIMENTAL
Intervention: alprazolam 0.5 mg
Number of subjects: 30
Study 3558328 — intervention group
Group type: COMPARATOR
Intervention: lorazepam
Number of subjects: 30
Study 3558328 — intervention group
Group type: COMPARATOR
Intervention: alprazolam
Number of subjects: 30
Study 31567609 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,500-nm nonablative fractional laser (NAFL)
Number of subjects: 100
Study 31567609 — intervention group
Group type: COMPARATOR
Intervention: 10,600-nm ablative fractional laser (AFL)
Number of subjects: 100
Study 31567609 — intervention group
Group type: COMPARATOR
Intervention: Both NAFL and AFL
Number of subjects: 100
Study 30542407 — intervention group
Group type: EXPERIMENTAL
Intervention: tiotropium bromide combined with budesonide/formoterol
Number of subjects: 180
Study 30542407 — intervention group
Group type: COMPARATOR
Intervention: budesonide/formoterol (control group)
Number of subjects: 180
Study 25711125 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental presence at clinical bedside rounds (PPCBR)
Number of subjects: 72
Study 25711125 — intervention group
Group type: COMPARATOR
Intervention: Non-parental presence at clinical bedside rounds (non-PPCBR)
Number of subjects: 72
Study 23833867 — intervention group
Group type: EXPERIMENTAL
Intervention: High-reward group
Number of subjects: 0
Study 23833867 — intervention group
Group type: COMPARATOR
Intervention: Low-reward group
Number of subjects: 0
Study 23833867 — intervention group
Group type: EXPERIMENTAL
Intervention: Compensation shock condition
Number of subjects: 0
Study 23833867 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-compensation shock condition
Number of subjects: 0
Study 20598123 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised implementation of the oral health care guideline and daily oral health care protocol
Number of subjects: 720
Study 20598123 — intervention group
Group type: COMPARATOR
Intervention: Non-supervised implementation of the oral health care guideline
Number of subjects: 720
Study 18249330 — intervention group
Group type: COMPARATOR
Intervention: Hepcon heparin management system (HMS)
Number of subjects: 0
Study 18249330 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified ACT-based heparinization
Number of subjects: 0
Study 17236474 — intervention group
Group type: EXPERIMENTAL
Intervention: Assistive technology supplement to the School Function Assessment
Number of subjects: 28
Study 17236474 — intervention group
Group type: COMPARATOR
Intervention: School Function Assessment
Number of subjects: 28
Study 14604321 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine
Number of subjects: 210
Study 14604321 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% ropivacaine plus 1 microg/mL fentanyl
Number of subjects: 210
Study 15244185 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 mg/m2 irinotecan every three weeks
Number of subjects: 0
Study 15244185 — intervention group
Group type: COMPARATOR
Intervention: 150 mg/m2 irinotecan once a week for four weeks followed by a two-week drug-free interval
Number of subjects: 0
Study 11220295 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 1.0 mg b.i.d.
Number of subjects: 380
Study 11220295 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosiglitazone 2.0 mg b.i.d.
Number of subjects: 380
Study 11220295 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study 7551204 — intervention group
Group type: EXPERIMENTAL
Intervention: Terfenadine 120 mg
Number of subjects: 28
Study 7551204 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg
Number of subjects: 28
Study 1722564 — intervention group
Group type: EXPERIMENTAL
Intervention: ABVP/LOPP (doxorubicin, bleomycin, vinblastine, prednisone alternating with lomustine, vincristine, procarbazine, prednisone)
Number of subjects: 80
Study 1722564 — intervention group
Group type: COMPARATOR
Intervention: COPP-Bleo (cyclophosphamide, vincristine, procarbazine, prednisone, low dose of bleomycin)
Number of subjects: 80
Study 7051404 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile perfusion
Number of subjects: 350
Study 7051404 — intervention group
Group type: COMPARATOR
Intervention: Non-pulsatile perfusion
Number of subjects: 350
Study 2861523 — intervention group
Group type: EXPERIMENTAL
Intervention: J5 antibody recipients
Number of subjects: 262
Study 2861523 — intervention group
Group type: COMPARATOR
Intervention: Control (plasma from donors before immunisation)
Number of subjects: 262
Study 30953222 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA-Protector
Number of subjects: 100
Study 30953222 — intervention group
Group type: COMPARATOR
Intervention: LMA-Supreme
Number of subjects: 100
Study 30515431 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg on day 1 and then 5 mg/kg once daily for 4 days)
Number of subjects: 0
Study 30515431 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (25 mg/kg/d twice‐daily for 5 days)
Number of subjects: 0
Study 30515431 — intervention group
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole (240 mg once daily for 5 days)
Number of subjects: 0
Study 30515431 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28606591 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSV∆G-ZEBOV-GP vaccine at 2×10^7 PFU dose
Number of subjects: 513
Study 28606591 — intervention group
Group type: EXPERIMENTAL
Intervention: rVSV∆G-ZEBOV-GP vaccine
Number of subjects: 513
Study 26253622 — intervention group
Group type: EXPERIMENTAL
Intervention: 20mg vortioxetine
Number of subjects: 24
Study 26253622 — intervention group
Group type: EXPERIMENTAL
Intervention: 40mg vortioxetine
Number of subjects: 24
Study 26253622 — intervention group
Group type: EXPERIMENTAL
Intervention: 20mg paroxetine
Number of subjects: 24
Study 26253622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 23018908 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (100/25 μg)
Number of subjects: 16000
Study 23018908 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (100 μg)
Number of subjects: 16000
Study 23018908 — intervention group
Group type: EXPERIMENTAL
Intervention: Vilanterol (25 μg)
Number of subjects: 16000
Study 23018908 — intervention group
Group type: COMPARATOR
Intervention: Matched placebo
Number of subjects: 16000
Study 21926181 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthocyanins (320 mg) in short-term study
Number of subjects: 150
Study 21926181 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthocyanins (320 mg/day) in long-term study
Number of subjects: 150
Study 21926181 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 21926181 — intervention group
Group type: EXPERIMENTAL
Intervention: Anthocyanins with NO-cGMP inhibitors
Number of subjects: 150
Study 18242276 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative statin use
Number of subjects: 555
Study 18242276 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity statin dosing (>= 40 mg atorvastatin)
Number of subjects: 555
Study 18242276 — intervention group
Group type: COMPARATOR
Intervention: No statin use (Control)
Number of subjects: 555
Study 16595499 — intervention group
Group type: EXPERIMENTAL
Intervention: rhTSH
Number of subjects: 63
Study 16595499 — intervention group
Group type: COMPARATOR
Intervention: THW
Number of subjects: 63
Study 12911777 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral challenges with egg
Number of subjects: 399
Study 12911777 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral challenges with peanut
Number of subjects: 399
Study 12911777 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral challenges with milk
Number of subjects: 399
Study 12911777 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral challenges with sesame
Number of subjects: 399
Study 12911777 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral challenges with peanut oil
Number of subjects: 399
Study 12911777 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral challenges with soy oil
Number of subjects: 399
Study 12911777 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral challenges with sunflower oil
Number of subjects: 399
Study 12911777 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral challenges with sesame oil
Number of subjects: 399
Study 11139003 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Stress Management (CBSM) intervention for 10 weeks
Number of subjects: 62
Study 11139003 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 62
Study 9086865 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure combined with hypnosis
Number of subjects: 64
Study 9086865 — intervention group
Group type: COMPARATOR
Intervention: Exposure in vivo
Number of subjects: 64
Study 9086865 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy
Number of subjects: 64
Study 9086865 — intervention group
Group type: EXPERIMENTAL
Intervention: Preference for treatment
Number of subjects: 64
Study 8385793 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 4 mg
Number of subjects: 12
Study 8385793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2868771 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS 201‐995 (25 micrograms/h)
Number of subjects: 5
Study 2868771 — intervention group
Group type: COMPARATOR
Intervention: Placebo (isotonic saline 125 ml/h)
Number of subjects: 5
Study 2868771 — intervention group
Group type: EXPERIMENTAL
Intervention: SMS 201‐995 (50 micrograms b.d. subcutaneously)
Number of subjects: 5
Study 29911906 — intervention group
Group type: EXPERIMENTAL
Intervention: Miniscrew‐anchored inverted Forsus FRD
Number of subjects: 16
Study 27855109 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate adaptations (no wait)
Number of subjects: 50
Study 27855109 — intervention group
Group type: COMPARATOR
Intervention: Usual adaptations (∼3-month wait)
Number of subjects: 50
Study 23959961 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance training (6-week full-body program)
Number of subjects: 0
Study 23959961 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 22872218 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 μg daily subcutaneous injection)
Number of subjects: 57
Study 22872218 — intervention group
Group type: COMPARATOR
Intervention: Bisphosphonate (17.5 mg weekly oral risedronate)
Number of subjects: 57
Study 22872218 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 57
Study 20689926 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted analysis including all patients
Number of subjects: 348
Study 20689926 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted analysis excluding patients with missing deferred consent
Number of subjects: 348
Study 17917707 — intervention group
Group type: COMPARATOR
Intervention: sCD40L levels measured in citrated plasma
Number of subjects: 2403
Study 17917707 — intervention group
Group type: COMPARATOR
Intervention: sCD40L levels measured in plasma
Number of subjects: 2403
Study 17917707 — intervention group
Group type: COMPARATOR
Intervention: sCD40L levels measured in serum
Number of subjects: 2403
Study 17917707 — intervention group
Group type: COMPARATOR
Intervention: sCD40L levels measured in serum vs plasma
Number of subjects: 2403
Study 16873787 — intervention group
Group type: EXPERIMENTAL
Intervention: sulfonylurea plus 1,000 microg Cr as CrPic
Number of subjects: 37
Study 16873787 — intervention group
Group type: COMPARATOR
Intervention: sulfonylurea plus placebo
Number of subjects: 37
Study 12791113 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.7 ml.kg-1 of 0.175% bupivacaine with 1 : 200 000 epinephrine
Number of subjects: 54
Study 12791113 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 ml.kg-1 of 0.175% bupivacaine with 1 : 200 000 epinephrine
Number of subjects: 54
Study 12791113 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.3 ml.kg-1 of 0.175% bupivacaine with 1 : 200 000 epinephrine
Number of subjects: 54